Effect of goal-directed haemodynamic therapy guided by non-invasive monitoring on perioperative complications in elderly hip fracture patients within an enhanced recovery pathway

Juan V. Lorente1,2,3*, Francesca Reguant2,4, Anna Arnau5,6,2, Marcelo Borderas4, Juan C. Prieto4, Jordi Torrallonada4, Laura Carrasco4, Patricia Solano4, Isabel Pérez4, Carla Farré4, Ignacio Jiménez7,3, Javier Ripollés-Melchor3,8, Manuel I. Monge3,9 and Joan Bosch2

Abstract

Background: Goal-directed haemodynamic therapy (GDHT) has been shown to reduce morbidity and mortality in high-risk surgical patients. However, there is little evidence of its efficacy in patients undergoing hip fracture surgery. This study aims to evaluate the effect of GDHT guided by non-invasive haemodynamic monitoring on perioperative complications in patients undergoing hip fracture surgery.

Methods: Patients > 64 years undergoing hip fracture surgery within an enhanced recovery pathway (ERP) were enrolled in this single-centre, non-randomized, intervention study with a historical control group and 12-month follow-up. Exclusion criteria were patients with pathological fractures, traffic-related fractures and refractures. Control group (CG) patients received standard care treatment. Intervention group (IG) patients received a GDHT protocol based on achieving an optimal stroke volume, in addition to a systolic blood pressure > 90 mmHg and an individualized cardiac index. No changes were made between groups in the ERP during the study period. Primary outcome was percentage of patients who developed intraoperative haemodynamic instability. Secondary outcomes were intraoperative arrhythmias, postoperative complications (cardiovascular, respiratory, infectious and renal complications), administered fluids, vasoressor requirements, perioperative transfusion, length of hospital stay, readmission and 1-year survival.

Results: In total, 551 patients (CG=272; IG=279) were included. Intraoperative haemodynamic instability was lower in the IG (37.5% vs 28.0%; p=0.017). GDHT patients had fewer postoperative cardiovascular (18.8% vs 7.2%; p < 0.001), respiratory (15.1% vs 3.6%; p < 0.001) and infectious complications (21% vs 3.9%; p < 0.001) but not renal (12.1% vs 33.7%; p < 0.001). IG patients had less vasopressor requirements (25.5% vs 39.7%; p < 0.001) and received less fluids [2.600 ml (IQR 1700 to 2700) vs 850 ml (IQR 750 to 1050); p=0.001] than control group. Fewer patients required transfusion in GDHT group (73.5% vs 44.4%; p < 0.001). For IG patients, median length of hospital stay was shorter [11 days (IQR 8 to 16) vs 8 days; (IQR 6 to 11); p < 0.001] and 1-year survival higher [73.4% (95%CI 67.7 to 78.3 vs 83.8% (95%CI 78.8 to 87.7); p < 0.003].

*Correspondence: juanvictor.lorente@gmail.com
1 Anaesthesia and Critical Care Department, Juan Ramón Jiménez Hospital, Ronda Norte s/n, 21590 Huelva, Spain
Full list of author information is available at the end of the article
**Background**

Hip fracture represents an increasingly serious public health problem with a significant impact on life expectancy and economic burden (Veronese and Maggi 2018). Patients with hip fractures are at high risk of perioperative complications (Reguant et al. 2019) due to a limited cardiorespiratory reserve when facing the fracture and surgery-associated stress (Cowan et al. 2017). Moreover, postoperative complications related to hip fracture are a known independent risk factor for mortality (Griffiths et al. 2021).

Enhanced recovery pathways (ERP) comprise perioperative evidence-based care interventions designed to improve outcomes after surgery (Ljungqvist et al. 2017). Perioperative haemodynamic optimization is a key element of the ERP (Miller et al. 2015). The goal-directed haemodynamic therapy (GDHT) has been shown to reduce morbidity and mortality in high-risk surgical patients (Giglio et al. 2016). Nevertheless, in daily clinical practice, patients with hip fracture are usually intraoperatively monitored with routine haemodynamic parameters such as blood pressure and heart rate (Reguant et al. 2019). However, these standard physiological variables result insufficient for assessing an adequate balance between oxygen delivery (DO₂) and consumption (VO₂) (Lugo et al. 1993). This DO₂/VO₂ imbalance may eventually lead to intraoperative tissue hypoperfusion, facilitating the appearance of postoperative complications (Merry and Mitchell 2018).

Currently, there are monitoring platforms that provide advanced haemodynamic parameters to guide GDHT in a non-invasive way to avoid the complications of invasive techniques (Teboul et al. 2016). The present study aimed to evaluate the effect of GDHT guided by non-invasive haemodynamic monitoring on perioperative complications in patients undergoing surgical hip fracture repair within an ERP.

**Methods**

This manuscript was written according to CONSORT statement. The study was approved by an independent Ethics Committee (Fundació Unio Catalana Hospitals) on 27 January 2015 (CEIC 15/03). All patients signed an informed consent to participate. The study was conducted according to the Declaration of Helsinki and all local legal and regulatory requirements. Trial registration: NCT02479321 (24/06/2015).

**Study design**

This is a single-centre, non-randomized, hospital-based intervention study with a historical control group (CG) and 12-month follow-up after hospital discharge.

**Inclusion/exclusion criteria**

Patients over 64 years with hip fracture within an ERP who underwent surgical treatment were included. Exclusion criteria were as follows: patients with pathological fractures, traffic-related fractures and refractures; patients with known contraindication or limitations to advanced haemodynamic monitoring with ClearSight® system and EV1000 platform (Edwards Lifesciences, Irvine, USA) (Saugel et al. 2015); patients with Raynaud disease, with aortic valve prosthesis, proximal aortic aneurysm, known intracardiac shunts; moderate to severe mitral or aortic regurgitation; moderate to severe aortic or mitral stenosis; patients with poor-quality arterial waveform signal (see below) and patients with significant preoperative psychomotor agitation.

**Conduct of the study**

**Perioperative management common to both groups**

Both groups were treated during the perioperative period in a multidisciplinary ERP unit created in 2010 exclusively dedicated to patients undergoing hip fracture repair (Reguant et al. 2019).

This unit’s objectives were to optimize patient health status before surgery, minimize preoperative stress, prevent and/or treat electrolyte imbalance, prevent and/or treat cardiovascular, respiratory, infectious and cognitive disorders, improve nutritional status and reduce surgical delay. The team comprised orthopaedic surgeons, anaesthesiologists, internists, a nurse case manager, a social worker, a physiotherapist and a nutritionist.

The main interventions of this multidisciplinary ERP unit for patients with hip fracture are shown in Table 1.

**Conclusions:** The use of GDHT decreases intraoperative complications and postoperative cardiovascular, respiratory and infectious but not postoperative renal complications. This strategy was associated with a shorter hospital stay and increased 1-year survival.

**Trial registration:** ClinicalTrials.gov NCT02479321.

**Keywords:** Enhanced recovery after surgery, Enhanced recovery pathway, Fluid therapy, Goal-directed haemodynamic therapy, Hip fracture, Intraoperative complications, Mortality, postoperative complications
Intraoperative period

All subjects received standard of care with a 3-lead electrocardiogram, pulse oximetry and two peripheral intravenous lines. Patients in both groups received standard measures to maintain oxygen saturation by pulse oximetry >94% and heart rate <100 beats/min. Anaesthetic technique was at the discretion of the anaesthetist.

Post-anaesthetic care unit (PACU)

After surgery, patients were treated in the PACU. The attendant physician determined discharge from this unit according to the local protocol.

Study arms

Control group

Data from patients who underwent surgery for hip fracture between October 2010 and November 2011 with follow-up to December 2012 were used for the CG (Reguant et al. 2019).

Haemodynamic management was at the discretion of the attending anaesthetist, using fluid therapy with crystalloids (0.9% saline, lactated Ringer or Isofundin®), colloids (Voluven®, Gelaspan®) and/or cardiovascular drugs (in bolus—epinephrine, or continuous infusion—noradrenaline, dobutamine).

Non-invasive, intermittent arterial pressure measurement was obtained at least every 5 min using a cuff (Dahtex Ohmeda-GE S/5 Aespire®).

Intervention group

Data from patients who underwent surgery for hip fracture between June 2015 and February 2018 with follow-up to March 2019 were used as the IG. Pre- and intraoperative non-invasive haemodynamic monitoring was conducted using ClearSight® monitor (Edwards Lifesciences, Irvine, USA). This monitoring system is based on the volume clamp method to continuously measure arterial pressure and the Physiocal method that periodically recalibrates the system (Saugel et al. 2015). Baseline haemodynamic measurements were taken when the Physiocal value exceeded 30 (Wesseling et al. 1995). If a Physiocal value over 30 was not obtained after 7 min monitoring, the patient was excluded due to a poor-quality arterial waveform signal (Wesseling et al. 1995).

Haemodynamic optimisation was performed according to the following GDHT protocol.

GDHT protocol (Fig. 1)

Three groups of cardiac index (CI) goals were formed according to age and prior functional capacity expressed...
Phase 1: Preoperative resuscitation

Measure SVI

250 ml FB

SVI increases > 10%?

NO

YES

Phase 2: Post-incision optimization

Measure SVI

100 ml FB

SVI increases > 10%?

NO

YES

Set intraoperative SVI Trigger

Phase 3: Maintenance during surgery

SVI < Trigger SVI
CIR
SAP < 90 mmHg

Monitor fluid losses

NO

YES

SVI < SVI trigger

NO

YES

CI < CI goal

NO

YES

IVOPOX

Vasopressor

SAP < 90 mmHg

NO

YES

SVI increases > 10%?

NO

YES

SAP < 90 mmHg

Fig. 1 Algorithms for goal-directed haemodynamic therapy phases
in metabolic equivalents (METS) (Montenij et al. 2014)

Additional file 1.

Fluids were given based on a protocolized haemodynamic algorithm to achieve and maintain an adequate indexed stroke volume (SVI) using crystalloids (0.9% Saline, Lactated Ringer or Isofundin ®) or colloids (if preoperative glomerular filtration rate was above 60 mL/min using Modification of Diet in Renal Disease (MDRD) equation (Ishihara 2014)- Voluven ®, Gelaspan ®). Choice of fluid type was based on anaesthesiologist criteria.

If a fluid bolus (FB) was not indicated and/or the target perfusion pressure was not achieved with its infusion, vasopressor was administered to maintain systolic arterial pressure (SAP) above 90 mmHg (in bolus—ephedrine, phenylephrine, or continuous infusion—noradrenaline) or continuous infusion of dobutamine was added to achieve in addition, the individualized CI goal.

Phase 1: Preoperative resuscitation

On arrival in the surgical area, patients received a FB of 250 ml of 5 min. If SVI increased by 10% or more (First Fluid Bolus Responder), the fluid bolus was repeated (Cecconi et al. 2011). Fluid boluses of 250 ml were repeated until the SVI failed to increase by 10%.

Once preoperative resuscitation was completed, prophylactic antibiotic was infused (Table 1). This fluid contribution covered the estimated insensible losses during surgery (Jacob et al. 2007).

Phase 2: Post-incision optimisation

Post-incision optimisation began 15 min after the surgical incision, if the haemodynamic stabilization was achieved (SAP and heart rate variation < 10% for 3 min); meanwhile, the haemodynamic priority was the maintenance of arterial pressure above goal set (Tassoudis et al. 2011). Fluid boluses of 100 ml were administered of less than 3 min (Guinot et al. 2015; Mallat et al. 2015; Marik 2015; Muller et al. 2011). If SVI rose >10%, the 100 ml fluid bolus was repeated. The trigger SVI during surgery was calculated by subtracting 10% from the SVI obtained from the last positive 100 ml fluid bolus (Muñoz et al. 2016).

Phase 3: Maintenance during surgery

If at least one of the following objectives, SVI>SVI trigger and/or SAP>90mmHg, were not achieved, SVI was analysed:

- If it was lower than the trigger SVI, a 100 ml FB was administered.
- If SVI was higher than trigger SVI, we look at the CI.
  - If its value was under goal level, dobutamine was added.
  - When CI was above goal level, a vasopressor was chosen.

After each therapy, we re-evaluated the achievement of SAP and SVI goals.

Measurements and data handling

Procedure

Intraoperative haemodynamic parameters (arterial pressure, heart rate, SpO2 in CG and also CI and SVI in IG) were registered at 15-min intervals. Haemodynamic instability, between intervals, was registered as an event in the next record. Fluids and cardiovascular drugs used from the patient’s arrival in the surgical area to their admission to the PACU were collected. In both groups, the evaluation of intraoperative complications was based on the intraoperative anaesthesia charts, whereas the postoperative complications were documented in the clinical course and hospital discharge report.

Post-discharge follow-up consisted of a structured telephone interview at 1, 3, 6 and 12 months after surgery. When the information could not directly be obtained from the patients (including deceased patients), the interview was done with next of kin or carer.

Assessment of outcomes

Primary outcome measures

The primary outcome was the percentage of patients who developed intraoperative haemodynamic instability, defined as one measurement of SAP < 90 mmHg in the CG and for at least 1 min in the IG and/or the need for a bolus of vasoconstrictor.

Secondary outcome measures

- Intraoperative arrhythmias: defined as electrocardiographic evidence of cardiac rhythm disturbance.
- Postoperative complications, grouped as follows:
  - Major cardiovascular complications: acute myocardial infarction, acute pulmonary oedema, ischemic stroke, pulmonary thromboembolism and cardiorespiratory arrest.
• Minor cardiovascular complications: haemodynamic instability, defined as one measurement of SAP < 90 and arrhythmias.
• Respiratory: hypoxia, defined as oxygen saturation <92%. Other respiratory complications: decompensation of chronic obstructive pulmonary disease, acute respiratory infection (clinical and radiological diagnosis and antibiotic treatment) and others.
• Renal: presence of at least one of the following: oligoanuria, defined as urine output under 0.5ml/kg per hour, including absence of urine output. Acute renal failure, defined as an increase in urea > 50 mg/dl and creatinine levels > 1.09 mg/dl in any analysis during admission.
• Infections: surgical wound (infection within 30 days after surgery that involves only skin and subcutaneous tissue of the incision), urinary (positive urine culture causing patient’s symptoms and which were not present on admission to hospital), systemic (fever >38 °C and positive blood antigen test with appropriate antimicrobial therapy instituted by a physician).
• Surgical reintervention during hospital stay.

− Total intraoperative volume and type of administered fluids, doses of cardiovascular drugs used, perioperative packed red blood cell transfusion, length of hospital stay, readmission within 30 days of surgery, and survival within 12 months after surgery.

Statistical analysis

Sample size
The rate of intraoperative haemodynamic instability described with standard of care was 37.5% (Reguant et al. 2019). We planned a relative risk reduction of 30% in IG.

To achieve a power of 80% using a bilateral \( \chi^2 \) test for two independent samples with a level of significance of 0.05, 538 patients had to be included (269 patients in each group). With a potential dropout of 5%, 568 patients were included.

The percentage of patients who developed one or more postoperative complications in CG was 45.2%. A meta-analysis by Grocott and colleagues suggested a RR reduction of 0.68 for complications in patients undergoing major surgery (Grocott et al. 2013). A sample size of 568 patients, 284 in each group, would have 80% power to detect a reduction of at least 22% in the number of IG patients presenting one or more postoperative complications, using a bilateral \( \chi^2 \) test for two independent samples.

Primary outcome
Details of intraoperative complications are shown in Table 3. The number of patients with intraoperative haemodynamic instability was lower in IG (37.5% vs 28.0%; \( p=0.017 \)). The median number of episodes of intraoperative haemodynamic instability in IG was lower than in the CG [2 (IQR 1 to 4) vs 1 (IQR 1 to 2), \( p<0.001 \)].
Secondary outcomes

Intraoperative arrhythmias

IG patients developed fewer arrhythmias than CG patients (2.2% vs 0.7%; \( p=0.172 \)).

Postoperative complications

Postoperative complications are shown in Table 3. Postoperative complications rates were 42.3% in the IG versus 45.2% in CG (\( p=0.489 \)). Patients in the IG had fewer cardiovascular complications (18.8% vs 7.2%; \( p<0.001 \)), fewer respiratory complications (15.1% vs 3.6%; \( p<0.001 \)) and postoperative infections (21% vs 3.9%; \( p<0.001 \)). However, IG patients had more renal complications (12.1% vs 33.7%; \( p<0.001 \)). No differences in postoperative renal complications were observed between groups in patients with normal creatinine value at hospital admission. (Additional file 4).

Fluid volumes, vasopressor doses and perioperative transfusion

Details of fluid volumes and vasopressor doses in both groups are shown in Table 4.

29.4% of IG patients were responders to the first fluid bolus performed. Patients in the IG received less fluid [2.600 ml (IQR 1700 to 2700) vs 850 ml (IQR 750 to 1050); \( p=0.001 \)] and vasopressors (39.7% vs 25.5%; \( p<0.001 \)) than CG. Lactated Ringer’s was the fluid most used during the intraoperative period in CG patients (73.9% vs 4.3%; \( p<0.001 \)) while saline was chosen more often in the intraoperative period in IG (25% vs 95.7%; \( p=0.001 \)). Fewer patients in IG received colloids than in CG (59.2% vs 9%; \( p<0.001 \)). Fewer patients required packed red blood cells (PRBC) transfusion in IG (73.5% vs 44.4%; \( p<0.001 \)), with a lower median number of PRBC among transfused patients in IG [2 (IQR 2 to 4) vs 2 (IQR 1 to 2); \( p<0.001 \)].
Length of stay and survival within 12 months of surgery

The median length of stay was shorter for patients in the IG (median days: 11 vs 8; \( p < 0.001 \)) (Table 3).

Demographic and clinical variables associated with 1-year mortality in the bivariate analysis appear in Additional file 2. Figure 3 shows the Kaplan–Meier survival curves for both groups. The likelihood of 1-year survival was higher in IG (log-rank test = 9.17; \( p = 0.003 \)) (see Fig. 3), with a crude HR of 0.56 (95% CI 0.39 to 0.82). Multivariate analysis (Additional file 3) showed that independent prognostic factors for 1-year survival were as follows: age (HR 1.09; 95% CI 1.05 to 1.12), male gender (HR 2.10; 95% CI 1.43 to 3.11), low (HR 2.33; 95% CI 1.29 to 4.23) and high comorbidity (HR 2.84; 95% CI 1.67 to 4.83), according to the Charlson Index, postoperative cardiovascular complications (HR 3.85; 95% CI 2.49 to 5.96), need for reintervention (HR 5.31; 95% CI 1.58 to 17.86) and belonging to the intervention group*. The adjusted HR for the IG was 0.61 (95% CI 0.39 to 0.95).

Discussion

The use of GDHT guided by non-invasive haemodynamic monitoring in patients undergoing hip fracture surgery within an ERP, was associated with a reduction in intraoperative complications (haemodynamic instability, arrhythmias) and postoperative cardiovascular, respiratory and infectious complications, but not postoperative renal complications. This strategy was also associated with a shorter hospital stay and increased survival 1 year after surgery.

Preoperative chronic conditions and insufficient preoperative optimization in this patient profile, associated with intraoperative conditions such as bleeding and hypovolemia, predispose these elderly patients to haemodynamic instability or arrhythmias during surgery (Alecu et al. 2010); (Rocos et al. 2017). The occurrence of intraoperative complications may compromise the balance between tissue oxygen delivery and oxygen consumption and increase the patient’s susceptibility to postoperative complications (Merry and Mitchell 2018); (Beecham et al. 2020).

Our results showed a significant decrease in intraoperative haemodynamic instability episodes in patients in the IG, similarly to a recently published study (Davies et al. 2019). In addition, patients in the IG had fewer postoperative cardiovascular, respiratory and infectious complications. These results may be due to improvements in haemodynamic control of these patients as a result of GDHT guided by a non-invasive monitoring system implemented. One of its main objectives is to avoid

### Table 2 Baseline characteristics according to group allocation

|                      | Control (CG) n=272 | Intervention (IG) n=279 |
|----------------------|--------------------|-------------------------|
| **Age**              | 84.9 ± 6.2         | 85.2 ± 7.4              |
| 65 to < 75 years     | 15 (5.5%)          | 30 (10.8%)              |
| 75 to < 85 years     | 125 (46.0%)        | 97 (34.8%)              |
| ≥ 85 years           | 132 (48.5%)        | 152 (54.5%)             |
| **Gender**           |                    |                         |
| Male                 | 84 (30.9%)         | 68 (24.4%)              |
| Female               | 188 (69.1%)        | 211 (75.6%)             |
| **ASA**              |                    |                         |
| I–II                 | 85 (31.2%)         | 41 (14.7%)              |
| III–IV               | 187 (68.8%)        | 238 (85.3%)             |
| **Charlson comorbidity index** |            |                         |
| Absence de comorbidity (0–1) | 125 (46.0%) | 109 (39.1%)            |
| Low comorbidity (2)  | 50 (18.4%)         | 57 (20.4%)              |
| High comorbidity (3 or more) | 97 (35.7%) | 113 (40.5%)            |
| **Cardiovascular history** |                |                         |
| Valvulopathy         | 21 (7.7%)          | 31 (11.1%)              |
| Arrhythmia           | 73 (26.8%)         | 58 (20.8%)              |
| Ischemic cardiopathy | 17 (6.3%)          | 29 (10.4%)              |
| Pulmonary thromboembolism (PTE) | 1 (0.4%) | 3 (1.1%)               |
| Hypertension         | 177 (65.1%)        | 212 (76.0%)             |
| **Total number of drugs** | 6 (IQR 4 to 8) | 7 (IQR 3 to 10)        |
| ≤ 4 drugs            | 89 (32.7%)         | 68 (24.4%)              |
| > 4 drugs            | 183 (67.3%)        | 211 (75.6%)             |
| **Type of fracture** |                    |                         |
| Intra‑capsular       | 121 (44.5%)        | 124 (44.4%)             |
| Extra‑capsular       | 151 (55.5%)        | 155 (55.6%)             |
| **Haemoglobin at admission** |            |                         |
| Haemoglobin > 12 g/dl| 159 (58.5%)        | 169 (60.6%)             |
| Haemoglobin ≤ 12 g/dl| 113 (41.5%)        | 110 (39.4%)             |
| **Creatinine at admission** |            |                         |
| Creatinine ≤ 1.09 mg/dl | 178 (65.7%) | 175 (62.7%)           |
| Creatinine > 1.09 mg/dl | 93 (34.3%) | 104 (37.3%)           |
| **Anaesthesia**      |                    |                         |
| General              | 28 (10.3%)         | 28 (10.0%)              |
| Spinal               | 244 (89.7%)        | 251 (90.0%)             |
| **Type of implant**  |                    |                         |
| Hip prosthesis       | 103 (37.9%)        | 102 (36.6%)             |
| Dynamic hip screw    | 122 (44.9%)        | 57 (20.4%)              |
| Intramedullary nail  | 43 (15.8%)         | 118 (42.3%)             |
| Others               | 4 (1.5%)           | 2 (0.7%)                |
| **Surgical delay**   |                    |                         |
| ≤ 48 h               | 150 (55.1)         | 191 (68.5)              |
| > 48 h               | 122 (44.9)         | 88 (31.5)               |
| **Surgery time (minutes)** | 80 (IQR 65 to 105) | 90 (IQR 70 to 120)     |

Mean ± Standard deviation; n (%); median (IQR 25th percentile to 75th percentile)
### Table 3  Main and secondary outcomes at 1-year follow-up

|                          | Control (CG) n=272 | Intervention (IG) n=279 | p-value  |
|--------------------------|--------------------|-------------------------|----------|
| **Intraoperative complications** |                    |                         |          |
| Hemodynamic instability  | 102 (37.5%)        | 78 (28.0%)              | 0.017a   |
| No. of episodes of hemodynamic instability | 2 (IQR 1 to 4) | 1 (IQR 1 to 2) | <0.001b |
| Arrhythmias              | 6 (2.2%)           | 2 (0.7%)                | 0.172c   |
| **Postoperative complications** |                    |                         |          |
| Cardiovascular           |                    |                         |          |
| Major                    |                    |                         |          |
| Myocardial infarction    | 1 (0.4%)           | 0 (0.0%)                | 0.494c   |
| Cardiorespiratory arrest | 3 (1.1%)           | 6 (2.2%)                | 0.505c   |
| Acute pulmonary edema    | 8 (2.9%)           | 5 (1.8%)                | 0.374a   |
| Pulmonary thromboembolism| 0 (0.0%)           | 0 (0.0%)                | -        |
| Cardiorespiratory arrest | 0 (0.0%)           | 0 (0.0%)                | -        |
| Minor                    |                    |                         |          |
| Haemodynamic instability | 40 (14.7%)         | 12 (4.3%)               | <0.001a  |
| Arrhythmias              | 34 (12.5%)         | 5 (1.8%)                | <0.001a  |
| Others                   | 2 (0.7%)           | 1 (0.4%)                | 0.620c   |
| Respiratory              |                    |                         |          |
| Myocardial infarction    | 41 (15.1%)         | 10 (3.6%)               | <0.001a  |
| Hypoxia                  | 17 (6.3%)          | 2 (0.7%)                | <0.001a  |
| Decompensation of chronic obstructive pulmonary disease | 6 (2.2%) | 1 (0.4%) | 0.066c |
| Acute respiratory infection | 16 (5.9%) | 5 (1.8%) | 0.012d |
| Others                   | 3 (1.1%)           | 2 (0.7%)                | 0.682c   |
| Renal                    |                    |                         |          |
| Surgical wound           | 57 (21.0%)         | 11 (3.9%)               | <0.001a  |
| Urinary                  | 8 (2.9%)           | 0 (0.0%)                | 0.003c   |
| Systemic                 | 3 (1.1%)           | 2 (0.7%)                | 0.682c   |
| Infections               |                    |                         |          |
| Hematoma/infection/neurological lesion | 0 (0.0%) | 0 (0.0%) | - |
| Surgical reintervention  | 6 (2.2%)           | 0 (0.0%)                | 0.014c   |
| Length of stay (days)    | 11 (IQR 8 to 16)   | 8 (IQR 6 to 11)         | <0.001b  |
| Destination after discharge |                   |                         |          |
| Convalescence            | 128 (49.8%)        | 142 (52.0%)             | 0.327a   |
| Family home              | 81 (31.5%)         | 71 (26.0%)              |          |
| Residence                | 48 (18.7%)         | 60 (22.0%)              |          |
| Thirty-day readmission   | 29 (11.3%)         | 21 (7.7%)               | 0.157a   |
| Survival                 |                    |                         |          |
| 1 month                  | 91.2% (87.1 to 94.0%) | 96.8% (93.9 to 98.3%) |          |
| 3 months                 | 86.6% (84.2 to 91.8%) | 95.3% (92.1 to 97.3%) |          |
| 6 months                 | 83.0% (78.0 to 87.0%) | 90.2% (86.0 to 93.2%) |          |
| 12 months                | 73.4% (67.7 to 78.3%) | 83.8% (78.8 to 87.7%) |          |

Mean ± Standard deviation; n (%); median (range x to y) or median (IQR 25th percentile to 75th percentile)

* Pearson χ²; † Mann–Whitney U; ‡ Fisher’s exact test; § Log-rank test

* In patients with haemodynamic instability
## Table 4  Total fluid volumes, vasopressor doses and perioperative blood transfusion

|                     | Control (CG) n=272 | Intervention (IG) n=279 | p-value |
|---------------------|--------------------|-------------------------|---------|
|                     | n (%) Median (IQR) | n (%) Median (IQR)      |         |
| **Fluid volumes**   |                    |                         |         |
| Total fluids (ml)   | 272 (100%) 2600 (IQR 1700 to 2700) | 279 (100%) 850 (IQR 750 to 1050) | 0.001 |
| Fluid creep -antibiotic prophylaxis - (ml) | 272 (100%) 200 (IQR 200 to 200) | 279 (100%) 200 (IQR 100 to 200) | 0.001 |
| Intraoperative fluids (ml) | 272 (100%) 2500 (IQR 2000 to 2500) | 279 (100%) 700 (IQR 550 to 900) | 0.001 |
| **Crystalloids (ml)** | 253 (94.5%) 2000 (IQR 2000 to 2000) | 278 (99.6%) 650 (IQR 550 to 850) | 0.001 |
| Saline (ml)         | 68 (25.0%) 1000 (IQR 1000 to 1000) | 267 (95.7%) 650 (IQR 550 to 850) | 0.001 |
| Lactated Ringer (ml) | 201 (73.9%) 1000 (IQR 1000 to 1000) | 12 (4.3%) 1050 (IQR 850 to 1237) | 0.889 |
| Isofunden® (ml)     | 22 (8.1%) 500 (IQR 500 to 500) | - |         |
| **Colloids (ml)**   | 161 (59.2%) 500 (IQR 500 to 500) | 25 (9.0%) 300 (IQR 200 to 500) | 0.001 |
| Voluven® (ml)       | 153 (56.3%) 500 (IQR 500 to 500) | 25 (9.0%) 300 (IQR 200 to 500) | 0.001 |
| Gelaspan® (ml)      | 11 (4.0%) 500 (IQR 500 to 500) | - |         |
| **Vasopressor**     | 108 (39.7%) 71 (25.5%) | <0.001 |
| Ephedrine (mg)      | 108 (39.7%) 15 (IQR 10 to 30) | 65 (23.3%) 10 (IQR 10 to 20) | 0.002 |
| Phenvylephrine (mg) | - | 11 (4.0%) 100 (IQR 50 to 150) | - |
| Noradrenaline (mg)  | 2 (0.7%) 3.5 (IQR 2 to 3.5) | - |         |
| **Blood transfusion** | 200 (73.5%) - | 124 (44.4%) - | <0.001 |
| Number of PRBCa     | 2 (IQR 2 to 4) - | 2 (IQR 1 to 2) - | <0.001 |
| **Fluid Challenge Responder** | - | 82 (29.4%) - |         |

Median (IQR 25th percentile to 75th percentile)
PRBC packed red blood cells
* About transfused patients

**Fig. 3** Kaplan–Meier survival curves according to group allocation. Crude hazard ratio for 1-year survival
intraoperative hypoperfusion (Brienza et al. 2019) which may have been reflected in fewer postoperative complications in IG.

A higher incidence of postoperative acute kidney injury (AKI) found in IG may be due to several reasons. First, patients in the IG have more risk factors for postoperative AKI, including age, female sex, hypertension and chronic kidney disease. (Meersch et al. 2017). Secondly, patients treated with GDHT received higher amounts of 0.9% saline. Hyperchloremic acidosis associated with saline infusion is detrimental to renal artery blood flow velocity and renal cortical tissue perfusion (Chowdhury et al. 2012). Third, the AKI definition itself. A single and transient, postoperative serum creatinine elevation above a very sensitive level was considered a renal complication. An isolated elevation could neither be associated with kidney cell damage (Hahn 2015) nor be significant compared to baseline value. In patients with normal creatinine value at hospital admission, no differences in the risk of suffering postoperative renal complications were observed between the groups. The limitations of AKI definition and the influence on mortality only by postoperative creatinine elevations associated with kidney cell damage, may explain a significant decrease in mortality 1 year after surgery, despite an increase in postoperative renal complications in IG.

The GDHT protocol applied in this study differs from that used in the most recent trials in this patient profile (Bartha et al. 2013; Davies et al. 2019; Moppett et al. 2015). The GDHT protocol used by Bartha and colleagues includes fluid resuscitation prior to anaesthetic induction, intraoperative use of vasoactive support if SAP declined by more than 30% from pre-anaesthesia values, and optimisation with fluids and dobutamine for stroke volume (SV) and DO₂ respectively. Colloid therapy to optimize SV was protocolised by Moppett and co-workers in their IG. Finally, Davies and colleagues applied a GDHT protocol based on SV optimisation by crystalloids and mean arterial pressure maintenance above 30% of baseline values with vasopressors.

Our IG shows a similar percentage of responders to the first fluid challenge as previously described (Bartha et al. 2013). This lower-than-expected percentage can be explained by the optimisation starting immediately after admission to hospital, according to the ERP applied in both patient cohorts. Total fluid used in our IG is comparable or slightly less than the amounts given in two previous studies’ intervention groups: 1.078 (Bartha et al. 2013) and 850 ml (Davies et al. 2019) respectively and slightly higher than the volume given in another previous intervention group: 750 ml (Moppett et al. 2015). A lower use of vasopressors in our IG stands out, probably because of following a decision algorithm. The non-application of a haemodynamic algorithm may lead to an early use of vasopressors, even if it is not physiologically appropriate for the patient’s condition. No IG patients were treated intraoperatively with dobutamine, probably due to the establishment of an individualized CI goal and by the absence of intraoperative pathophysiological tributary situations. Fewer patients had been transfused in our IG. In addition to the use of less bleeding surgical techniques (Yu et al. 2015), patients in IG may suffered less haemodilution than patients in CG due to lower amount of fluids received (Ince 2015).

We found a reduction in hospital stay and a significant increased survival in IG patients throughout the first year after surgery. These findings can be explained by the significant reduction in intraoperative complications and postoperative cardiovascular, respiratory and infectious complications, and surgical reinterventions (Monk et al. 2015); (Roche et al. 2005). After adjusting for potential confounding variables, IG membership was a protective factor for 1-year mortality.

The results of this study suggest that not only haemodynamic strategy we perform on our patients will influence their outcomes, the type of fluid used during major surgery may also affect postoperative results (Heming et al. 2020). The results of the fluid infusion strategy used cannot be evaluated without considering the type of drug used.

Our study has some limitations. It was a single-centre, non-randomized design with a 3-year gap between the two study groups. However, no changes were made between groups in the ERP, nor in the composition of the multidisciplinary team or in the care protocols during the study period. IG recruitment rate was lower than expected, probably because of the real emergency surgery status applied to hip fracture patients in this hospital since 2010. Patients with contraindications for haemodynamic monitoring, with poor-quality signal obtained or with preoperative psychomotor agitation that prevented haemodynamic monitoring were excluded only from the IG. However, our exclusion rate for these reasons (9%) is lower than previously reported (Davies et al. 2019), but we cannot rule out that these excluded patients had worse clinical status on arrival in the operating theatre.

Uncontrolled before-and-after study provides less quality evidence than randomized controlled trials (RCT) (Sedgwick 2014). However, this design offers valuable insights into the potential benefits of GDHT protocols under real-life conditions and can complement evidence from RCT (Saugel et al. 2019). Moreover, this is the largest sample size published to date evaluating the effect of GDHT guided by non-invasive haemodynamic monitoring during hip fracture surgery.
Conclusions
In patients undergoing hip fracture surgery, the use of a GDHT protocol guided by non-invasive haemodynamic monitoring was associated with a reduction in intraoperative complications and postoperative cardiovascular, respiratory and infectious, but not postoperative renal complications. This strategy was also associated with shorter hospital stay and higher survival 1 year after surgery.

Abbreviations
AKI: Acute kidney injury; CG: Control group; CI: Cardiac Index; DO2: Oxygen delivery; ERP: Enhanced recovery pathway; FB: Fluid bolus; GDHT: Goal-directed haemodynamic therapy; HR: Hazard ratio; IG: Intervention group; IQR: Interquartile range; MDRD: Modification of Diet in Renal Disease; METS: Metabolic equivalents; PACU: Post-anesthetic care unit; PRBC: Packed red blood cells; SAP: Systolic arterial pressure; SpO2: Oxygen saturation; SV: Stroke volume; SVI: Indexed stroke volume; VO2: Oxygen consumption.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13741-022-00277-w.

Additional file 1.. Intraoperative cardiac index goal groups.
Additional file 2.. Bivariant analysis. Prognostic factors of 1-year mortality. Crude Hazard Ratio (HR) and statistical significance according to bivariate Cox regression models.
Additional file 3.. Multivariant analysis. Independent prognostic factors for mortality. Adjusted HR for 1-year survival.
Additional file 4.. Renal complications according creatinine at admission and group allocation.

Acknowledgements
We would like to acknowledge the contribution of Dr Omar El Boutrouki and Ms Mercé Castejón for their help in the development of the study.

Authors’ contributions
JVL: study design, patient recruitment, acquisition of data, review of perioperative complications in IG, analysis and interpretation of data, writing up of the paper and final approval of the version to be published. FR: study design, patient recruitment, acquisition of data, review of perioperative complications in CG, analysis and interpretation of data and review of the paper’s content. MB: patient recruitment, acquisition of data and review of the paper’s content. JCM: patient recruitment, acquisition of data and review of the paper’s content. JCP: patient recruitment, acquisition of data and review of the paper’s content. AA: study design, analysis and interpretation of data and review of the paper’s content. MB: patient recruitment, acquisition of data and review of the paper’s content. JRM: analysis and interpretation of data and review of the paper’s content. JC: patient recruitment, acquisition of data and review of the paper’s content. JT: patient recruitment, acquisition of data and review of the paper’s content. JCP: patient recruitment, acquisition of data and review of the paper’s content. JPS: patient recruitment, acquisition of data and review of the paper’s content. IP: patient recruitment, acquisition of data and review of the paper’s content. JL: analysis and interpretation of data and review of the paper’s content. JJ: study design, analysis and interpretation of data and review of the paper’s content. All authors have approved the latest version of the manuscript and agree to be responsible for all aspects of the work ensuring that issues relating to the accuracy or completeness of any part of the work have been properly investigated and resolved.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

Availability of data and materials
The datasets used and/or analysed during this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This manuscript was written according to CONSORT statement. The study was approved by an independent Ethics Committee (Fundación Unio Catalana Hospitals, Chairperson: Dr. Miquel Nolla) on 27 January 2015 (CEIC 15/03). All patients signed an informed consent to participate. The study was conducted according to the Declaration of Helsinki and all local legal and regulatory requirements.

Consent for publication
Not applicable.

Competing interests
Dr Lorente, Dr Jiménez, Dr Ripollés-Melchor and Dr Monge have received conference fees from Edwards Lifesciences.
Dr Lorente & Dr Ripollés-Melchor have received conference fees from Fresenius Kabi and bioMérieux.
Dr Ripollés-Melchor & Dr Monge have received conference fees from Dextera Medical.
Dr Lorente has received conference fees from Vifor Pharma, Grifols and financial support for research obtained through Edwards Lifesciences Grant Portal.
Economic research support from bioMérieux.
Dr Ripollés-Melchor has received conference fees from MSD.
The rest of the authors declare that they have competing interests.

Author details
1 Anaesthesia and Critical Care Department, Juan Ramón Jiménez Hospital, Ronda Norte s/n, 21590 Huelva, Spain. 2 School of Medicine and Health Sciences, International University of Catalunya (UIC), Barcelona, Spain. 3 Fluid Therapy and Hemodynamic Group of the Hemostasis, Transfusion Medicine and Fluid Therapy Section, Spanish Society of Anesthesia and Critical Care (SEDAR), Madrid, Spain. 4 Department of Anaesthesiology, Althaia Xanxa Assistencial Universitària, Manresa, Spain. 5 Central Catalonia Chronicity Research Group (C3RIG), Research and Innovation Unit, Althaia Xanxa Assistencial Universitària, Manresa, Spain. 6 Centre d’Estudis Sanitaris i Socials, (CESS), Universitat de Vic–Universitat Central de Catalunya (UVIC-UCC), Vic, Spain. 7 Clinical Management Anesthesiology Unit, Resuscitation and Pain Therapy, Virgen del Rocio Hospital, Sevilla, Spain. 8 Anesthesia and Critical Care Department, Infanta Leonor Hospital, Madrid, Spain. 9 Intensive Care Unit, Hospital Universitario SAS, Jerez de la Frontera, Spain.

Received: 22 December 2021 Accepted: 13 July 2022
Published online: 10 August 2022

References
Alecu C, Cugnet-Royer E, Mertes PM, Salvi P, Vespiognani H, Lambert M, et al. Pre-existing arterial stiffness can predict hypotension during induction of anaesthesia in the elderly. Br J Anaesth. 2010;105(5):583–8. Published by Elsevier Ltd. https://doi.org/10.1093/bja/aeq231.
Bartha E, Arfwedson C, Immund A, Fernlund ME, Andersson LE, Kalman S. Randomized controlled trial of goal-directed haemodynamic treatment in patients with proximal femoral fracture. Br J Anaesth. 2013;110(4):S45–53.
Bechem G, Gusack R, Vencen S. Hypotension during hip fracture surgery and postoperative morbidity. Ir J Med Sci Irish J Med Sci. 2020;189(3):1087–96.
Brienza N, Biancofere G, Cavaliere F, Corcone A, de Gasperi A, de Rosa RC, et al. Clinical guidelines for perioperative hemodynamic management of non cardiac surgical adult patients. Minerva Anestesiol. 2019;85(12):1315–33.
Cecconi M, Parsons AK, Rhodes A. What is a fluid challenge? Curr Opin Crit Care. 2011;17(3):390–5.
Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline...
and plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg. 2012;256(1):18–24.

Cowan R, Lim JH, Ong T, Kumar A, Sahota O. The challenges of anaesthesia and pain relief in hip fracture care. Drugs Aging. 2017;34(1):1–11 Springer International Publishing.

Davies SJ, Yates DR, Wilson RF, Murphy Z, Gibson A, Allgar V, et al. A randomised trial of non-invasive cardiac output monitoring to guide haemodynamic optimisation in high risk patients undergoing urgent surgical repair of proximal femoral fractures (ClearOF trial NCT02382185). Perioper Med. 2019;8(30):1–11.

Gigliolo M, Manca F, Dalfino L, Biennia N. Perioperative hemodynamic goal-directed therapy and mortality: a systematic review and meta-analysis with meta-regression. Minerva Anestesiol. 2016;82(11):1199–213.

Griffiths R, Babu S, Dixon P, Freeman N, Hurford D, Kelleher E, et al. Guideline for the management of hip fractures 2020: Guideline by the Association of Anaesthetists. Anaesthesia. 2021;76(2):225–37.

Grocott MP, Dushantha N, Hamilton MA, Mythen MG, Harrison D, Rowan K. Perioperative increase in global blood flow to explicit defined goals and outcomes after surgery: a cochrane systematic review. Br J Anaesth. 2013;111(4):535–48. The Author(s).

Guinot PG, Bernard E, Defrance F, Pietot S, Majoub Y, Dupont H, et al. Mini-fluid challenge predicts fluid responsiveness during spontaneous breathing under spinal anaesthesia: an observational study. Eur J Anaesthesiol. 2015;32(9):645–9.

Hahn RG. Renal injury during hip fracture surgery: an exploratory study. Anest‑ejol Intens Ter. 2015;47(4):284–90.

Heming N, Moine P, Coscas R, Annane D. Perioperative fluid management for major elective surgery. Br J Surg. 2020;107(2):e56–62.

Ince C. Hemodynamic coherence and the rationale for monitoring the micro-circulation. Crit Care. 2015;19(Suppl 3):S8 BioMed Central Ltd. Available from: http://www.ccmforum.com/content/19/S3/S8.

Ishihara H. Kidney function after the intraoperative use of 6% tetrastarches (HES 130/0.4 and 0.42). J Anesth. 2014;28(2):249–56.

Jacob M, Chappell D, Hofmann-Kiefer K, Conzen P, Peter K, Rehm M. Determinants of insensible fluid loss. Perspiration, pressure shift and endothelial glycocalyx. Anaesthesia. 2007;62(8):747–64.

Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152(3):292–8.

Lugo G, Arizpe D, Dominguez GRM, et al. Relationship between oxygen consumption and oxygen delivery during anesthesia in high-risk surgical patients. Crit Care Med. 1993;21(1):64–9.

Mallat J, Meddour M, Durville E, Lemyze M, Pepy F, Temime J, et al. Decrease in pulse pressure and stroke volume variations after mini-fluid challenge accurately predicts fluid responsiveness. Br J Anaesth. 2015;115(3):449–56.

Mark PE. Fluid therapy in 2015 and beyond: the mini-fluid challenge and mini-fluid bolus approach. Br J Anaesth. 2015;115(3):347–9.

Meersch M, Schmidt C, Zarbock A. Perioperative acute kidney injury: an underestimated problem. Anesth Analg. 2017;125(4):1223–32.

Mery AF, Mitchell SJ. Complications of anaesthesia. Anaesthesia. 2018;73:7–11.

Miller TE, Roche AM, Mythen M. Fluid management and goal-directed therapy as an adjunct to Enhanced Recovery After Surgery (ERAS). Can J Anaesth. 2015;62(2):158–68.

Monk TG, Bonsert MR, Henderson WG, Mangione MP, Sum-Ping STJ, Bentt DR, et al. Association between intraoperative hypotension and hypertension and 30-day postoperative mortality in noncardiac surgery. Anesthesiology. 2015;123(2):307–19 Available from: https://insights.ovid.com/crossref?an=00000542-201508000-00016.

Montenjol L, De WE, Frank M, Van BP, De WA, Kruitwagen C, et al. Influence of early goal-directed therapy using arterial waveform analysis on major complications after high-risk abdominal surgery: study protocol for a multicenter randomized controlled superiority trial. 2014. p: 1–12.

Moppett IK, Rowlands M, Mannings A, Moran CG, Wiles MD, Van DeWalt G, et al. LiDCO-based fluid management in patients undergoing hip fracture surgery under spinal anaesthesia, a randomized trial and systematic review. Br J Anaesth. 2015;115(4):444–59.

Muñoz JL, Gallardo T, Miranda E, Berrio DL, Ruiz-tovar J, Ronda JM, et al. Goal-Directed Fluid Therapy on Laparoscopic Sleeve Gastroctomy in Morbidly Obese Patients. Obes Surg. 2016;26(11):2648–53.

Reguant F, Anau A, Lorente JV, Maestro L, Bosch J. Efficacy of a multidisciplinary approach on postoperative morbidity and mortality of elderly patients with hip fracture. J Clin Anesth. 2019;53(September 2018):11–9. Elsevier. https://doi.org/10.1016/j.jclinane.2018.09.029.

Roche JJW, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and post‑operative complications on mortality after hip fracture in elderly people: Prospective observational cohort study. Br Med J. 2005;331(7529):1374–6.

Rocos B, Whitehouse MR, Kelly MB. Resuscitation in hip fractures: a systematic review. Br Med J. 2017;3(6159006):1–6.

Saigal B, Cecconi M, Wagner JY, Reuter DA. Noninvasive continuous cardiac output monitoring in perioperative and intensive care medicine. Br J Anaesth. 2015;114(4):562–75. https://doi.org/10.1093/bja/aeu447.

Saigal B, Joosten A, Scheeren TWL. Perioperative goal‑directed therapy: what’s the best study design to investigate its impact on patient outcome? J Clin Monit Comput. 2019;33(3):361–3. Springer Netherlands. https://doi.org/10.1007/s10877-018-0196-2.

Sedgwick P. Before and after study designs. BMJ. 2014;349(January):g5074.

Tassoudis V, Vretzakis G, Petsi S, Stamatiou G, Bouza K, Melekos M, et al. Impact of intraoperative hypotension on hospital stay in major abdominal surgery. J Anesth. 2011;25(4):492–9.

Teboul JL, Saigal B, Cecconi M, De Backer D, Hofer CK, Monnet X, et al. Less invasive hemodynamic monitoring in critically ill patients. Intensive Care Med. 2016;42(9):1350–9 Springer Berlin Heidelberg.

Veronese N, Maggi S. Epidemiology and social costs of hip fracture. Injury. 2018;49(8):1483–90. Elsevier Ltd. https://doi.org/10.1016/j.injury.2018.04.015.

Wesseling KH, de Wit B, Van der Hoeven A, Van Goudoever JSJ. Physiological, calibrating finger vascular physiology for Finapres. Homeostasis. 1995;362–367–82.

Yu J, Zhang C, Li L, Kwong JSW, Xue L, Zeng X, et al. Internal fixation treatments for intertrochanteric fracture: a systematic review and meta‑Analysis of randomized evidence. Sci Rep. 2015;5(June):1–11. https://doi.org/10.1038/srep18195 Nature Publishing Group.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.